Current Appointments & Affiliations
Assistant Professor of Surgery
·
2024 - Present
Surgery, Vascular and Endovascular Surgery,
Surgery
Recent Publications
Incidence and risk factors for hemodialysis access-induced distal ischemia after hemodialysis reliable outflow (HeRO) surgery.
Journal Article J Vasc Access · February 6, 2026 BACKGROUND: Hemodialysis Reliable Outflow (HeRO) graft is vital for complex hemodialysis patients who have exhausted all other access options. Hemodialysis access-induced distal ischemia (HAIDI) is a serious complication, however, risk factors for HAIDI af ... Full text Link to item CiteLeveraging the Transfer Center to Improve Access to Vascular Surgical Care at a Tertiary Academic Medical Center.
Journal Article Ann Vasc Surg · February 2026 BACKGROUND: Vascular surgeons are essential to maintaining a safe operating room environment for all surgical specialties, in addition to managing primary vascular diseases. The value of the vascular surgery service line within a health-care system has bee ... Full text Link to item CiteImpact of Antiplatelet and Anticoagulation Therapy on Hemodialysis Reliable Outflow Graft Patency.
Journal Article Ann Vasc Surg · December 2025 BACKGROUND: The Hemodialysis Reliable Outflow (HeRO) graft combines an arteriovenous graft with a central venous stent, allowing for hemodialysis access in patients with end-stage renal disease limited by central venous stenosis. The impact of anticoagulat ... Full text Link to item CiteRecent Grants
Prospective, non-randomized staged pivotal clinical study to assess the safety and performance of the Xeltis Hemodialysis Access graft: Xeltis aXess US Pivotal
Clinical TrialPrincipal Investigator · Awarded by Xeltis, Inc. · 2025 - 2036A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients with End-Stage Renal Disease
Clinical TrialPrincipal Investigator · Awarded by W. L. Gore & Associates, Inc. · 2024 - 2032A Phase 3 Randomized Study to Compare the Efficacy and Safety of the Humacyte Human Acellular Vessel (HAV) with that of an Autogenous Arteriovenous Fistula (AVF) in Female Patients with End-Stage Renal Disease Requiring He- CLN-Pro-V012 - Pro00114567
Clinical TrialPrincipal Investigator · Awarded by Humacyte Global, Inc. · 2024 - 2032View All Grants
Education
Boston University, School of Medicine ·
2012
M.D.
Boston University ·
2008
M.A.
Johns Hopkins University ·
2005
M.S.
Johns Hopkins University ·
2004
B.S.